Vigeo Reports Completion of VT1021 in P-I/II Study for the Treatment of Recurrent Glioblastoma and Pancreatic Cancer
Shots:
- The P-I/II dose expansion studies evaluate the safety & preliminary anti-tumor efficacy of VT1021 as monothx. in patients with dose-escalation & expansion cohorts with rGBM & PC. The results of both studies are expected in Q4’21
- In the rGBM expansion cohort- the therapy showed a complete tumor regression & PR- patients remain on trial for ~9mos. & continue to receive therapy in an open-label extension study. In PC expansion cohort- reduction in tumor with measurable disease & able to reprogram tumor immune microenvironment from immune-suppressive to immune-responsive
- The company plans to initiate a P-II/III study of VT1021 for newly diagnosed & recurrent GBM patients at the end of 2021
| Ref: Vigeo | Image: Reuter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com